The company said the late-stage study for its pelacarsen drug missed its primary objective of reducing the risk of cardiovascular events like death, heart attack and stroke compared with placebo.
Source link
About The Author
Novartis Shares Fall After Heart Drug Misses Target in Late-Stage Trial